Latest News

Novavax says COVID vaccine triggers immune response to Omicron variant

© Reuters. FILE PHOTO: Vials labelled “VACCINE Coronavirus COVID-19” and a syringe are seen in front of a displayed Novavax logo in this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration

By Carl O’Donnell

(Reuters) – Novavax Inc’s COVID-19 vaccine is effective in generating an immune response against the Omicron variant, according to early data published on Wednesday, suggesting that the U.S. drugmaker’s existing COVID-19 vaccine can help combat the new Omicron variant.

Novavax’s two-dose, protein-based vaccine was authorized for use this week by European Union regulators and the World Health Organization. [L1N2T50VX] It has previously been approved by countries including Indonesia and the Philippines but not the United States.

Novavax said that receiving an additional booster dose of Novavax’s vaccine further increased people’s immune response to Omicron. The data was taken from Novavax’s ongoing studies of its vaccine’s effectiveness in adolescents and as a booster.

“We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials,” said Gregory M. Glenn, Novavax’s president of research and development.

Other COVID-19 vaccine manufacturers, including Pfizer Inc. (NYSE:PFE) and Moderna (NASDAQ:MRNA) Inc., also increase immune responses to Omicron, early data from those companies has shown. Resistance in all cases is stronger in people who have received an additional booster dose.

Novavax is working on developing an Omicron-specific vaccine and said Wednesday it expects to begin manufacturing doses of the variant-specific shot in January.

The drugmaker will start shipping vaccines to the EU’s 27 member states in January as part of its deal to supply up to 200 million doses.

The company will also begin shipments in early 2022 to COVAX, a vaccine distribution mechanism overseen by WHO that allocates COVID-19 shots to poorer countries. Novavax and its partner, Serum Institute of India, have agreed to send COVAX more than 1.1 billion doses of Novavax’s vaccine.

Novavax says COVID vaccine triggers immune response to Omicron variant

Disclaimer:Fusion Mediawould like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

You may also like

Leave a reply

Your email address will not be published.

More in Latest News